






An Adaptive, Implementation-to-Target cRCT


using remote records and opt-out inclusion to embed guideline-adherent delirium care in UK palliative care units



DAMPen-Delirium II is an adaptive implementation-to-target, Type III hybrid effectiveness-implementation parallel group cluster randomised controlled trial (cRCT) across 20 UK PCUs (10 per arm, ~50 patient records per cluster at each timepoint).



The design emphasises efficiency and low burden on local teams by




Results

Our study design focuses on minimal data collection by PCU site staff with our central study team accessing electronic medical notes remotely. The central study team held information sessions where we described the study which led to a total of 43 sites showing interest in joining the study with of a target of only 20 sites required.

The Confidentiality Advisory Group approval for an opt-out strategy materially decreased burden on site staff while maintaining patient rights regarding data.

Interest from 43 potential sites indicates strong feasibility for delivering a national implementation trial in typically research-naïve PCU environments.



Discussion

DAMPen-Delirium II demonstrates several methodological innovations applicable beyond palliative care :

